Webinar Overview
PANIC Spring Webinar
As the importance and number of Oligonucleotide therapeutics grows, so too does the need for characterization methodologies both during drug development and production. Because structure is so intricately entwined in therapeutic efficacy for this class of drug, detailed characterization of structure is critical. Nuclear Magnetic Resonance (NMR) can deliver detailed structural information that spans the breadth of the different oligonucleotide-base therapies being developed. This webinar will detail some of the latest advancements in NMR oligonucleotide-based drug characterization.
Tuesday, 12 March 2024, 11:00 ES
Presentations
- The vital role of NMR in analyzing nucleic acids’ structure and dynamics for small molecule drug discovery advancements
Celestine Chi, AstraZeneca - Multi-attribute assessment of anti-sense therapeutics
Robert Brinson, IBBR, NIST - NMR of RNA and therapeutic oligonucleotides
Martial Piotto, Bruker BioSpin
Key Learning Topics
- Different approaches to the characterization of oligonucleotide therapeutic with NMR
- Pharmaceutical trends and requirements for oligonucleotide-based therapeutics
- Latest developments from Bruker to address requirements in characterization of oligonucleotide and other macromolecular therapeutics.
Speakers
Celestine Chi
Biophysics, Discovery Sciences, R&D, AstraZeneca, Gothenburg, Sweden
Dr. Celestine Chi is a distinguished researcher with expertise in the realm of molecular sciences. He received his Ph.D. from Uppsala University, Sweden with Prof. Per Jemth, delving deeply into the intricacies of protein folding and binding. Celestine then pursued a postdoctoral position at ETH, Zurich with Prof. Roland Riek. He returned to Uppsala University before moving onto industry. Celestine currently serves as an NMR specialist and Senior Scientist at AstraZeneca in Gothenburg, Sweden, focusing on unlocking the enigmatic world of non-coding genomes, unravelling structural dynamics and pioneering novel methodologies to target these entities with precision using small molecules.
Robert Brinson
Research Chemist in the Biomolecular Structure and Function Group at the Institute for Bioscience and Biotechnology Research (IBBR), a joint research institute of the University of Maryland and NIST, in Rockville, Maryland
Robert applies biophysical measurements to define structure and dynamics of nucleic acids, proteins, and glycoproteins. Robert seeks to push the limits of NMR methodologies to define the critical quality attribute of higher order structure for drug substances. He received his Ph.D. in chemistry from Wake Forest University, then entered the field of structural biology as a NIH/NIST NRC postdoctoral fellow under John Marino (NIST) and Stuart Le Grice (NCI). Under their direction, Robert performed high resolution NMR studies on important nucleic acid elements from various viruses.
Dr. Martial Piotto
Pharma product manager of Biologics solutions
Martial Piotto obtained his Ph.D. in NMR spectroscopy at the University of Purdue, USA (Pr. D. Gorenstein). He then joined Bruker France as head of NMR application where he worked on various aspects of NMR spectroscopy, notably the development of new pulse sequences and HRMAS technology. Over the years, he grew an interest in applications of NMR in the pharmaceutical and medical fields. His work currently focusses on the characterization of Biologics (mAb, vaccines and therapeutic oligonucleotides) by combining NMR and multivariate statistical tools.